The Generation of Carcinogenic Etheno-DNA Adducts in the Liver of Patients with Nonalcoholic Fatty Liver Disease

Overview

Journal Hepatobiliary Surg Nutr

Publisher AME Publishing Company

Date 2015 May 26

PMID 26005678

Citations 15

Authors

Kirsten-Berit Linhart

Katharina Glassen

Teresa Peccerella

Rudiger Waldherr

Heinz Linhart

Helmut Bartsch

Helmut K Seitz

Affiliations

Soon will be listed here.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD), in particular its more aggressive form nonalcoholic steatohepatitis (NASH) is increasingly observed as a cause of end stage liver disease and hepatocellular carcinoma (HCC). Reactive oxygen species (ROS) are an important factor in the pathogenesis of HCC. ROS can react with polyunsaturated fatty acids derived from membrane phospholipids resulting in the production of reactive aldehydes as lipid oxidation (LPO) byproducts, such as 4-hydroxynonenal (4 HNE). 4 HNE can react with DNA to form mutagenic exocyclic etheno-DNA adducts. ROS is induced by inflammatory processes, but also by induction of cytochrome P450 2E1 (CYP2E1), as seen with chronic alcohol consumption.

Methods: Immunohistochemical detection of CYP2E1, 4 HNE and hepatic exocyclic etheno-DNA adducts was performed on liver sections from 39 patients with NFLD. Spearman rank correlation was calculated to examine possible correlations.

Results: Exocyclic etheno-DNA adducts were detected and correlated significantly with 4 HNE, but not with CYP2E1.

Conclusions: This is the first description of highly carcinogenic exocyclic etheno-DNA adducts in NAFLD patients. We could show that exocyclic etheno-DNA adducts significantly correlated with lipid peroxidation product 4 HNE, but not with CYP2E1, implying that in NAFLD ROS generation with consecutive DNA damage is rather inflammation driven through various cytokines than by induction of CYP2E1.

Citing Articles

TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.

Wang X, Zeldin S, Shi H, Zhu C, Saito Y, Corey K J Hepatol. 2021; 76(4):910-920.

PMID: 34902531 PMC: 8934258. DOI: 10.1016/j.jhep.2021.11.031.

Sequence Dependent Repair of 1,-Ethenoadenine by DNA Repair Enzymes ALKBH2, ALKBH3, and AlkB.

Qi R, Bian K, Chen F, Tang Q, Zhou X, Li D Molecules. 2021; 26(17).

PMID: 34500720 PMC: 8434105. DOI: 10.3390/molecules26175285.

Enzymatic bypass and the structural basis of miscoding opposite the DNA adduct 1,N-ethenodeoxyguanosine by human DNA translesion polymerase η.

Ghodke P, Mali J, Patra A, Rizzo C, Guengerich F, Egli M J Biol Chem. 2021; 296:100642.

PMID: 33839151 PMC: 8121704. DOI: 10.1016/j.jbc.2021.100642.

The Role of Lipoxidation in the Pathogenesis of Diabetic Retinopathy.

Augustine J, Troendle E, Barabas P, McAleese C, Friedel T, Stitt A Front Endocrinol (Lausanne). 2021; 11:621938.

PMID: 33679605 PMC: 7935543. DOI: 10.3389/fendo.2020.621938.

A Comprehensive Review on Source, Types, Effects, Nanotechnology, Detection, and Therapeutic Management of Reactive Carbonyl Species Associated with Various Chronic Diseases.

Fuloria S, Subramaniyan V, Karupiah S, Kumari U, Sathasivam K, Unnikrishnan Meenakshi D Antioxidants (Basel). 2020; 9(11).

PMID: 33147856 PMC: 7692604. DOI: 10.3390/antiox9111075.

References

Nair J, Nair U, Sun X, Wang Y, Arab K, Bartsch H . Quantifying etheno-DNA adducts in human tissues, white blood cells, and urine by ultrasensitive (32)P-postlabeling and immunohistochemistry. Methods Mol Biol. 2010; 682:189-205. DOI: 10.1007/978-1-60327-409-8_14. View

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R . Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37(4):917-23. DOI: 10.1053/jhep.2003.50161. View

Schaffner F, Thaler H . Nonalcoholic fatty liver disease. Prog Liver Dis. 1986; 8:283-98. View

Albano E . Alcohol, oxidative stress and free radical damage. Proc Nutr Soc. 2006; 65(3):278-90. DOI: 10.1079/pns2006496. View

Eberle G, Barbin A, Laib R, Ciroussel F, Thomale J, Bartsch H . 1,N6-etheno-2'-deoxyadenosine and 3,N4-etheno-2'-deoxycytidine detected by monoclonal antibodies in lung and liver DNA of rats exposed to vinyl chloride. Carcinogenesis. 1989; 10(1):209-12. DOI: 10.1093/carcin/10.1.209. View

Barbin A . Etheno-adduct-forming chemicals: from mutagenicity testing to tumor mutation spectra. Mutat Res. 2000; 462(2-3):55-69. DOI: 10.1016/s1383-5742(00)00014-4. View

Ong J, Younossi Z . Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 2007; 11(1):1-16, vii. DOI: 10.1016/j.cld.2007.02.009. View

Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T . Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology. 2005; 41(1):64-71. DOI: 10.1002/hep.20543. View

Ascha M, Hanouneh I, Lopez R, Tamimi T, Feldstein A, Zein N . The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010; 51(6):1972-8. DOI: 10.1002/hep.23527. View

10.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

11.

Pandya G, Moriya M . 1,N6-ethenodeoxyadenosine, a DNA adduct highly mutagenic in mammalian cells. Biochemistry. 1996; 35(35):11487-92. DOI: 10.1021/bi960170h. View

12.

Swenberg J, Fedtke N, Ciroussel F, Barbin A, Bartsch H . Etheno adducts formed in DNA of vinyl chloride-exposed rats are highly persistent in liver. Carcinogenesis. 1992; 13(4):727-9. DOI: 10.1093/carcin/13.4.727. View

13.

Cortez-Pinto H, Camilo M, Baptista A, De Oliveira A, de Moura M . Non-alcoholic fatty liver: another feature of the metabolic syndrome?. Clin Nutr. 2000; 18(6):353-8. DOI: 10.1016/s0261-5614(99)80015-6. View

14.

Chitturi S, Abeygunasekera S, Farrell G, Holmes-Walker J, Hui J, Fung C . NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002; 35(2):373-9. DOI: 10.1053/jhep.2002.30692. View

15.

Ludwig J, Viggiano T, MCGILL D, Oh B . Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55(7):434-8. View

16.

Wang Y, Millonig G, Nair J, Patsenker E, Stickel F, Mueller S . Ethanol-induced cytochrome P4502E1 causes carcinogenic etheno-DNA lesions in alcoholic liver disease. Hepatology. 2009; 50(2):453-61. DOI: 10.1002/hep.22978. View

17.

Seitz H, Stickel F . Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer. 2007; 7(8):599-612. DOI: 10.1038/nrc2191. View

18.

Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K . The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005; 143(10):722-8. DOI: 10.7326/0003-4819-143-10-200511150-00009. View

19.

Abdelmegeed M, Banerjee A, Yoo S, Jang S, Gonzalez F, Song B . Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. J Hepatol. 2012; 57(4):860-6. PMC: 3445664. DOI: 10.1016/j.jhep.2012.05.019. View

20.

Karin M, Greten F . NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005; 5(10):749-59. DOI: 10.1038/nri1703. View